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Background: The aim of this study was to assess airway hyperresponsiveness to eucapnic voluntary hyperventilation
and dry powder mannitol challenge in athletes aiming to participate at the Paralympic Games 2008 in Beijing,
especially in athletes with spinal cord injury.
Methods: Forty-four athletes with a disability (27 with paraplegia (group 1), 3 with tetraplegia (group 2) and 14 with
other disabilities such as blindness or single limb amputations (group 3) performed spirometry, skin prick testing,
measurement of exhaled nitric oxide, eucapnic voluntary hyperventilation challenge test (EVH) and mannitol
challenge test (MCT). A fall in FEV1 of ≥10% in either challenge test was deemed positive for exercise-induced
bronchoconstriction.
Results: Fourteen (32%) athletes were atopic and 7 (16%) had a history of physician-diagnosed asthma. Absolute
lung function values were significantly lower in patients of group 1 and 2 compared to group 3. Nine (20%)
athletes were positive to EVH (8 paraplegics, 1 tetraplegic), and 8 (18%) athletes were positive to MCT (7 paraplegics,
1 tetraplegic). Fourteen (22.7%) subjects were positive to at least one challenge; only three athletes were positive to
both tests. None of the athletes in group 3 had a positive test. Both challenge tests showed a significant association
with physician-diagnosed asthma status (p = 0.0001). The positive and negative predictive value to diagnose
physician-diagnosed asthma was 89% and 91% for EHV, and 75% and 86% for MCT, respectively.
Conclusion: EVH and MCT can be used to identify, but especially exclude asthma in Paralympic athletes.
Keywords: Disability, Eucapnic voluntary hyperventilation, Exercise-induced bronchoconstriction, Spinal cord injury,
Mannitol challenge, ParaplegiaBackground
Athletes participating at the Paralympic Games 2008 in
Beijing had to apply for a therapeutic use exemption if
they wished to use inhaled beta agonists as these were
prohibited substances according to the World Anti-
Doping Code Prohibited List [1]. They had to provide
objective criteria for the existence of exercise-induced
bronchoconstriction or exercise induced asthma according
to the World Antidoping Agency’s Therapeutic Use
Exemption Guidelines [2].
As exercise challenge tests are quite insensitive to
identify exercise induced bronchoconstriction in elite* Correspondence: jleuppi@uhbs.ch
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reproduction in any medium, provided the orathletes [3], easier but also standardized tests would be
needed. In addition, standardization with respect to both
workload and environmental conditions is almost im-
possible to achieve for sport-specific exercises in the
field [3], and even more so for disabled athletes. Provo-
cation challenge tests such as EVH and the MCT have
therefore been used to assess exercise-induced broncho-
constriction and asthma in athletes in a standardized
fashion. EVH, where athletes are required to hyper-
ventilate a dry air mixture at room temperature for
six minutes, has been established as a standardized
test to diagnose exercise-induced asthma [3,4] and has
been recommended in elite athletes [5,6]. MCT tests
athletes’ response to inhalation of dry powder mannitol
from a handheld device in increasing doses and has also
been shown to identify individuals with exercise-inducedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with EVH in able-bodied athletes [10].
Whether these tests can be used to assess athletes with a
disability, however, is unknown. We therefore set out to
test and compare EVH and MCT and their utility to diag-
nose exercise-induced asthma in elite athletes with a dis-
ability, in particular in athletes with spinal cord injury.
Methods
Athletes with a disability from the Swiss national team
who were planning to participate in the Paralympic Games
2008 in Beijing were asked to take part in the study. The
athletes answered questions about asthma, underwent skin
prick testing, spirometry, and exhaled nitric oxide (NO)
measurement and were subsequently challenged with EVH
and MCT on two separate occasions. The study was ap-
proved by the Ethics Committee of the Canton Lucerne,
Switzerland. All participants gave written informed con-
sent and the study was carried out in accordance with
the Declaration of Helsinki [11].
Subjects
Forty-four athletes with a disability were studied. Twenty-
seven (61.4%) were paraplegic (Group 1), 3 (6.8%) tetra-
plegic (group 2), and 14 (31.8%) with other disabilities such
as blindness or single limb amputation (group 3). All ath-
letes were non-smokers. The diagnosis of asthma was
based on previous physician-diagnosed asthma (a positive
answer to the following two questions: “Have you ever had
asthma?” and “Was this confirmed by a doctor?” and on
current symptoms) [12].
Skin-prick test
Each athlete underwent skin-prick testing to common
aeroallergens according to the SAPALDIA protocol [13].
Atopy was defined as having a positive reaction to one
of the allergens on skin-prick testing [13].
Lung function testing
Baseline lung function was performed in each athlete in the
sitting position using a nose clip according to standardized
guidelines [14]. For the measurement a MasterScreen Body
(Viasys Healthcare GmbH, Hoechberg, Germany) was
used. The spirometer was calibrated according to the sug-
gestions of the producer. The following parameters were
measured (total lung capacity (TLC), residual volume (RV),
functional residual capacity (FRC), vital capacity (VC),
endexpiratory reserve volume (ERV), forced vital capacity
(FVC), forced expiratory volume in one second (FEV1)).
Exhaled nitric oxide
Orally exhaled nitric oxide (FeNO) measurements were
performed prior to lung function and bronchial chal-
lenge testing according to published guidelines [15,16]using a device with a built-in biofeedback mechanism
(NIOX MINO, Aerocrine AB, Solna, Sweden) at a flow
rate of 50 mL/s.
Bronchoprovocation challenge tests
Each athlete underwent an EVH challenge test and a
MCT on separate days. Athletes with previous physician-
diagnosed asthma were asked to abstain from their regu-
lar medication one week prior to lung function testing.
Exercise-induced bronchoconstriction was defined as a
fall in FEV1 of ≥10% in either EVH challenge test and/or
MCT [9,17] (Figure 1).
1. Eucapnic voluntary hyperventilation
Before each test FEV1 was measured three times
and the highest value was taken as the baseline value
for determining maximal voluntary volume (MVV).
MVV was calculated as 35 × FEV1. Athletes were
then instructed to hyperventilate at minimum level
of 65% of their MVV for six minutes breathing a gas
mixture containing 5% CO2 and 21% O2. The
inhaled gas mixture was kept constant using the
Eucap Sys™ (SMTEC SA, Nyon, Switzerland).
Immediately following the challenge, FEV1 was
measured twice and the highest value was taken.
Measurements were repeated after 5, 10, 15 and
20 minutes. A fall of 10% or greater to baseline in
one time point was considered as positive [17].
2. Mannitol challenge
MCT was performed by administering dry mannitol
powder (Aridol™ Pharmaxis Ltd, Sydney, Australia),
inhaled from a dry powder device (Osmohaler,
Pharmaxis Ltd, Frenchs Forest, NSW, Australia) as
described previously by Anderson et al. [18]. FEV1
was measured 60 seconds after the delivery of each
dose (5, 10, 20, 40, 80, 160, 160, 160 mg). The test
continued until the FEV1 had fallen 15% or the
maximum cumulative dose of 635 mg had been
administered. A fall in FEV1 greater or equal to 10%
was noted positive for mannitol-induced
bronchoconstriction. PD10 (‘provoking dose-10’) was
defined as the cumulative dose of mannitol causing a
fall of 10% in FEV1. The response–dose ratio (RDR)
for mannitol was calculated by dividing the highest
percentage fall in FEV1 by the cumulative mannitol
dose needed to cause this fall. RDR was compared to
the fall in FEV1 in the EVH challenge.
Statistical analysis
Differences in subjects’ characteristics were analysed
using one way ANOVA, the Χ2 test or Fisher’s exact test
where appropriate. Interrater reliability (Kappa) was
used to examine the agreement between EVH and MCT.
A p-value of 0.05 or less was defined as statistically
Eucapnic voluntary hyperventilation
Measurement of FEV1 immediately after hyperventilation 
Measurement of FEV 1: 5 min after hyperventilation 
Measurement of FEV 1: 10 min after hyperventilation
Measurement of FEV 1: 15 min after hyperventilation
Measurement of FEV 1: 20 min after hyperventilation
3x Measurement of FEV1:  
highest value = baseline value 
Hyperventilation of dry air mixture containing 5% CO2 
for six minutes at  65% of MVV  
Calculation of MVV 
Positive test:
Fall in FEV1 10%  
to baseline 
Mannitol Challenge Test
Inhalation of dry mannitol powder 
Mannitol 5 mg  
Mannitol 0 mg  Measurement of FEV 1 = baseline value 
Measurement of FEV1 
Mannitol 10 mg  
Mannitol 15 mg  
Mannitol 20 mg  
Mannitol 40 mg  
Mannitol 80 mg  
Mannitol 160 mg  
Mannitol 160 mg  
Mannitol 160 mg  
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Measurement of FEV1 
Positive test:
Fall in FEV1 10% 
to baseline 
Figure 1 Bronchoprovocation challenge tests. MVV = maximal voluntary volume; FEV 1 = forced expiratory volume in one second.
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log transformed values of PD10 and RDRs. Responses to
EVH and MCT were compared using Spearman correl-
ation coefficients. Statistical analyses were performed
using GraphPad Prism Version 5.01 for Windows.
Results
Subjects
Of the forty-four participating athletes twenty-seven
(61.4%) were paraplegic (group 1), 3 (6.8%) tetraplegic
(group 2) and 14 (31.8%) had other disabilities such as
blindness or single limb amputation (group 3). Fourteen(31.8%) athletes were found to be atopic and seven (15.9%)
subjects had a history of physician diagnosed asthma;
eleven athletes (25%) were diagnosed with asthma after as-
sessment. The three groups did not show any statistically
significant differences in the mean age, weight, height or
gender distribution. Individual patient characteristics are
given in Table 1.
Baseline lung function
Results of baseline lung function testing are shown in
Table 2. As there are no standardized predicted values
for paraplegics and tetraplegics, we used absolute values
Table 1 Subject characteristics
Baseline characteristics Group 1 Group 2 Group 3 All p-value
(Paraplegics) (Tetraplegics) (Single limb amputees; blind athletes)
Number of athletes 27 3 14 44
Males (N, %) 16 (59.3%) 2 (66.7%) 12 (85.7%) 30 (68.2%) 0.23
Mean age years (SD) 34.1 (±12.2) 42.3 (±9.3) 33 (±8.6) 34.4 (±11) 0.45
Mean height cm (SD) 170 (±12.9) 166.3 (±15.6) 177.1 (±6.7) 172 (±11.8) 0.06
Mean weight kg (SD) 63.5 (±14.4) 63.7 (±25.1) 71 (±12.7) 65.9 (±14.7) 0.16
Atopy (N, %) 12 (44.4) 0 (0.0) 2 (14.3) 14 (31.8) 0.07
Legend: SD = standard deviation; p-values are given for the three neurologically defined groups.
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found between the three defined groups for VC, ERV,
FVC, and FEV1, with tetraplegics having the lowest values
for vital capacity and FEV1.
Exhaled NO
Exhaled NO did not differ significantly between the
three neurologically defined groups (Table 2), nor between
athletes with or without pre-existing asthma. There was
also no difference in the exhaled NO between athletes with
or without exercise-induced bronchoconstriction (either
MCT or EVH challenge test positive) (25.2 ppb vs.
33.1 ppb, p = 0.53). However we found a statistically signifi-
cant difference for athletes with atopy. These subjects had
significantly higher values of exhaled NO than those with-
out atopy (41.8 ppb, vs. 25.6 ppb, p = 0.03).
EVH challenge
Forty-one athletes completed the EVH challenge with a
mean ventilation of 82% MVV. Two athletes failed to
reach the proposed 65% MVV for an adequate test, but
ventilated not less than 63% of MVV. One athlete did
not complete the test. Nine subjects (21%) had a positive
EVH challenge. Of these, eight were paraplegics with aTable 2 Baseline lung function
Group 1 Group 2
(Paraplegics) (Tetraplegics) (Sin
Mean TLC L (SD) 6.54 (1.57) 5.34 (2.03)
Mean RV L (SD) 2.35(0.87) 2.03 (0.49)
Mean FRC L (SD) 3.34 (1.06) 2.57 (0.74)
Mean VC L (SD) 4.19 (0.99) 3.31 (1.74)
Mean ERV L (SD) 0.99 (0.44) 0.54 (0.38)
Mean FVC L (SD) 4.01 (0.88) 3.14 (1.76)
Mean FEV1 L (SD) 3.48 (0.68) 2.80 (1.75)
Mean NO ppb (SD) 31.2 (26.4) 51.7 (30.8)
Legend: L = liters; SD = standard deviation; TLC = total lung capacity; RV = reserve volum
reserve volume; FVC = forced vital capacity; FEV1= forced expiratory volume in one seco
groups (one-way ANOVA).mean fall in FEV1 of 15.74% (SD 5.4%) and one was
tetraplegic with an 11.6% fall in FEV1. None of the ath-
letes in group 3 had a positive test. Those with a nega-
tive test had a mean fall in FEV1 of 4.3% (SD 2.6%).
Seven of the paraglegic athletes and the tetraplegic
athlete had a diagnosis of asthma. A positive EVH
challenge was significantly more common in athletes
with asthma than without: eight athletes of eleven with
a positive history of asthma had a positive EVH chal-
lenge compared to only one without a history of asthma
(p < 0.001) (Table 3). The positive predictive value of
EVH to identify physician diagnosed asthma was 89%,
the negative predictive value 91%.MCT challenge
All subjects completed the challenge. Eight athletes (18.2%)
showed a fall in FEV1 > 10% after inhaling a maximal cu-
mulative dose of 635 mg of Mannitol, with a mean fall of
13% (SD 4.0%) (Table 3). The geometric mean value for
PD10 was 313 mg. Of the eight athletes with a positive
MCT, seven were paraplegic and one tetraplegic. The mean
maximum percentage fall in FEV1 in athletes that had a
negative MCT was 4.53% (SD 3.8%).Group 3 All p-value
gle limb amputees; blind athletes)
7.40 (1.80) 6.73 (1.73) 0.11
2.57 (1.21) 2.40 (0.97) 0.64
3.97 (1.46) 3.49 (1.23) 0.12
4.84 (0.77) 4.34 (1.04) 0.03
1.40 (0.48) 1.09 (0.50) <0.01
4.74 (0.77) 4.18 (1.00) 0.01
4.10 (0.68) 3.63 (0.83) 0.01
25.4 (7.8) 30.8 (22.9) 0.24
e; FRC = functional reserve volume; VC = vital capacity; ERV = endexpiratory
nd; p-values are given for the difference between the three neurologically defined









1 No 1 5.6 0.0
2 No 3 1.3 1.9
3 No 3 2.8 7.8
4 No 2 4.8 0.0
6 No 3 0.9 8.5
7 No 1 2.6 5.3
9 No 1 6.8 5.6
10 No 1 5.9 8.1
11 No 1 4.2 0.6
12 No 3 4.9 5.8
13 No 1 4.4 10.0
14 No 3 5.3 6.3
15 No 3 0.8 0.0
18 No 1 5.0 4.1
21 No 3 2.1 3.1
22 No 2 9.4 7.0
23 No 1 3.0 0.0
24 No 1 3.7 0.0
26 No 1 1.9 0.7
27 No 3 0.5 2.5
28 No 1 0 5.8
29 No 3 7.9 6.0
30 No 3 9.1 4.1
31 No 1 3.3 8.8
32 No 1 No test available 3.9
33 No 1 1.3 1.9
35 No 1 4.1 10.7
36 No 3 5.3 3.8
37 No 1 16.9 5.1
38 No 3 3.6 4.8
39 No 1 5.9 2.1
40 No 3 2.3 7.0
42 No 1 3.6 9.6
5 Yes 1 7.3 12.7
8 Yes 1 13.5 2.0
16 Yes 3 8.9 8.2
17 Yes 1 10 11.1
19 Yes 1 27.2 19.4
20 Yes 1 12.8 5.2
25 Yes 1 14.3 0.0
34 Yes 2 11.6 13.5
Table 3 Results of EVH and MCT (Continued)
41 Yes 1 8.5 14.9
43 Yes 1 18.4 21.5
44 Yes 1 12.8 7.8
Group 1: paraplegic; group 2: tetraplegic; group 3: blind or single limb amputation.
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had a positive test result in MCT compared to two ath-
letes without asthma (p = 0.001). The positive and nega-
tive predictive values of MCT to identify physician
diagnosed asthma were 75% and 86%, respectively.
Comparison between MCT and EVH challenge
Nine participants had a positive response to EVH and
eight had a positive response to the MCT. Ten of the
eleven athletes diagnosed with asthma had at least one
positive test for EVH or mannitol challenge. However,
only three athletes had a positive response to both
challenges resulting in a kappa of 0.19. Neither log-
transformed RDR for mannitol and fall in FEV1 after exer-
cise showed any correlation (r = −0.26; 95% CI: -0.53 to
0.043) nor log- transformed values of PD10 mannitol chal-
lenge and percentage of fall in FEV1 after EVH (r = −0.39;
95% CI: -0.86 to 0.44) (Figure 2 and 3).
Discussion
This is the first study reporting the feasibility of bronchial
challenge testing with EVH and MCT in athletes with dis-
abilities investigating for the existence of exercise-induced
bronchoconstriction or asthma. Ten of the eleven athletes
diagnosed by a physician with asthma had at least one
positive test for EVH or MCT challenge whereas threeFigure 2 Comparison of EVH challenge to mannitol challenge.
PD10 = provoking dose 10: cumulative dose in mg of Mannitol to
cause a 10% fall in FEV1 (forced expiratory volume in one second);
EVH = eucapnic voluntary hyperventilation; results of athletes with
positive tests on both challenges are circled.
Figure 3 Comparison of EVH challenge to mannitol challenge.
FEV1 = forced expiratory volume in one second; RDR = response
dose ratio.
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lenges. EVH and MCT had a high negative predictive value
and thus a negative challenge test would allow to exclude
asthma in this population.
Baseline lung function testing showed significant differ-
ences in VC, ERV, FVC and FEV1 between the groups with
spinal cord injury and the group of athletes with other dis-
abilities but no spinal cord injury. Athletes with tetraplegia
had lower lung function values compared to athletes with
paraplegia. Previous research reports that injury to the cer-
vical and upper thoracic spinal cord decreases the function
of inspiratory and expiratory respiratory muscles while the
expiration is more impaired in individuals with tetraplegia
or paraplegia and high spinal cord lesion [19-21].
The measured exhaled NO did not differ significantly
between athletes with spinal cord injury and athletes with-
out spinal cord injury, nor did it differ between subjects
with or without physician diagnosed asthma. However the
group of tetraplegic individuals tended to have higher NO
levels compared to those with lesions leading to paraplegia.
This is in concordance with another study reporting ele-
vated levels of exhaled NO in tetraplegic individuals that
were in the range of NO levels expected for individuals
with mild asthma [22]. However it is currently unclear if el-
evated exhaled NO levels in tetraplegic individuals are a re-
sult of increased activity of the inducible NO synthetase
due to inflammation or due to an altered regulation of in-
ducible NO synthetase [22].
In the 2012 version of the world anti-doping agency
prohibited list the use of all beta-2 agonists with the ex-
ceptions of salbutamol, formoterol and salmeterol are
prohibited and athletes that use these substances mustapply for exemption and provide objective criteria for
the existence of exercise-induced bronchoconstriction or
exercise induced asthma [23].
To our knowledge, this is the first study to evaluate
exercise-induced bronchoconstriction by EVH or manni-
tol in athletes with spinal cord injury. As exercise chal-
lenge testing is especially difficult to standardize in this
group of elite athletes, EVH and inhalation of dry pow-
dered mannitol are two options to diagnose exercise-
induced bronchoconstriction and allow the therapeutic
use of inhaled beta agonists during competition. Both
challenge tests showed a significant association with
physician diagnosed asthma. Both EVH and MCT were
shown to have a high negative predictive value which
suggests that a negative test can reliably exclude asthma
in this population of athletes with disabilities. The diag-
nostic validity of MCT in our study is similar to those
previously reported in able-bodied athletes [10,24,25].
In our group, 21% of all participants were identified as
having exercise-induced bronchoconstriction by eucapnic
hyperventilation. In other studies testing able-bodied elite
athletes exercise-induced bronchoconstriction was identi-
fied in 31% to 50% [10,26-28] by EVH challenge. This
difference cannot be explained by inadequate hyperventila-
tion as the minimum achieved ventilation equalled 63%
maximum voluntary volume and the mean ventilation was
82% MVV. Only two athletes failed to reach the proposed
65% MVV for an adequate test. The lower proportion of
positive EVH tests is in concordance with a relatively low
prevalence of physician diagnosed asthma in our study
sample. With the mannitol challenge, 18% tested positive
for exercise-induced bronchoconstriction, compared with
52% in an Australian able-bodied elite athlete population
[10]. None of the athletes without spinal cord injury had a
positive test result in our study group. The difference
might be explained by the inclusion of athletes of various
sporting disciplines, as substantial differences in the preva-
lence of exercise-induced asthma have been reported,
depending on the type of sport performed [29,30]. Low
prevalences of hyperresponsiveness to mannitol were pre-
viously reported for a population of elite cross country
skiers [17] as well as Scottish elite swimmers [24].
In the past, it was shown that the majority of patients
with tetraplegia demonstrate airway hyperresponsiveness
to methacholine [31,32], histamine [33] and ultrasonic-
ally nebulized distilled water [34]. One of the three tetra-
plegic athletes tested positive on MCT as well as on
EVH. This athlete showed the lowest vital capacity and
FEV1 of all athletes tested. It has been postulated that
with small airway diameters a small further reduction in
calibre induced by a bronchoconstrictive agent produces
a large increase in resistance as airway resistance is in-
versely proportional to the fourth power of the radius
[35]. The reduced airway calibre in these athletes does
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tetraplegia demonstrate airway hyperresponsiveness in
the MCT and EVH.
When testing 50 elite able-bodied athletes, Holzer
et al. demonstrated a strong association between the
response to MCT and to the EVH [10]. In our study, we
identified eight and nine athletes with a positive test
result, respectively. However, only three athletes had
congruent results on both challenges. Holzer et al. set
the cut-off defining a positive test at >10% fall in FEV1
in the MCT [10]. In a study testing children for bron-
chial hyperresponsiveness, Kersten set the cut-off for a
positive test result at > 15% in FEV1 in the MCT and
concluded that the MCT was especially useful to exclude
exercise-induced bronchoconstriction [36]. For children,
different cut-off points for exercise testing and inhala-
tional provocation tests are more suitable [37-39]. Had
we defined a 15% cut-off in our subjects, only 2 partici-
pants would have tested positive on the MCT with a single
athlete testing congruently positive on the MCT and the
EVH. With only adults included in the study, we chose a
cut-off of ≥10% fall in FEV1 in both challenge tests.
A significant relationship between the reactivity to
mannitol, defined by the response–dose-ratio (RDR),
and the fall in FEV1 after EVH could not be demon-
strated in our study. While Kersten and co-workers [36]
showed a strong relationship between RDR mannitol
and the fall in FEV1 after exercise in able-bodied chil-
dren, Clearie and co-workers could not find an associ-
ation between reacitivity to mannitol and standardized
field-based testing in elite swimmers [24].Conclusion
In conclusion, we present results of bronchial hyper-
responsiveness testing in a population of elite athletes
with a disability. EVH and MCT were found to be feas-
ible and safe in diagnosing exercise-induced asthma in
athletes with spinal cord injury. A combination of both
challenge tests is recommended in this group of sub-
jects. Eucapnic voluntary hyperventilation and inhalation
of dry powder mannitol can be used to identify, but
especially exclude asthma in Paralympic athletes due to
their relative high negative predictive value for the diag-
nosis of physician-diagnosed asthma.Competing interests
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